The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial. (clinicaltrials.gov) - Oct 2, 2026 - P3 | N=142 | Not yet recruiting | Sponsor: Guliz Ozgun | Trial completion date: Dec 2032 ➔ Dec 2033 | Initiation date: Apr 2026 ➔ Feb 2027 | Trial primary completion date: Dec 2030 ➔ Dec 2031
Trial completion date • Trial initiation date • Trial primary completion date • Genito-urinary Cancer • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor
|